nach oben

Erschienen in:

01.12.2011 | Positionspapier

Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter

Positionspapier der DGK 2011

verfasst von: Prof. Dr. B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer, Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie (DGK)

Erschienen in: Die Kardiologie | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Positionspapier der DGK zu Medikamente freisetzende Stents (DES) und mit Medikamenten beschichtete Ballonkatheter (DCB) fokussiert auf in Deutschland zugelassene und verfügbare Produkte, die in klinischen Studien untersucht wurden. Es sind für alle Produkte randomisierte, kontrollierte klinische Studien mit primärem angiographischem Endpunkt zum Nachweis der antirestenotischen Wirksamkeit und nachfolgend klinische Endpunktstudien zu fordern. Der Einsatz von DES führt im Vergleich zu unbeschichteten Stents (BMS) zu einer Reduktion erneuter Revaskularisationen, während sich die klinischen Endpunkte wie Tod oder Myokardinfarkt nicht ändern. DES sollten bevorzugt bei erhöhtem Risiko einer Instentstenose eingesetzt werden. Bei erhöhtem Risiko für eine Stentthrombose oder zu erwartenden Problemen bei einer verlängerten dualen Thrombozytenaggregationshemmung (DTAH) ist der Einsatz von BMS zu bevorzugen. Die Dauer einer DTAH beträgt 1 Monat nach BMS-Implantation, 1 Monat nach Therapie der BMS-ISR mit DCB, 6 bis 12 Monate nach DES-Implantation bei allen Patienten sowie grundsätzlich 12 Monate nach akutem Koronarsyndrom (ACS) unabhängig von der Art der Intervention.

Gruntzig A (1978) Transluminal dilatation of coronary-artery stenosis. Lancet 1(8058):263PubMedCrossRef

Moses JW et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14):1315–1323PubMedCrossRef

Stone GW et al (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350(3):221–231PubMedCrossRef

Joner M et al (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48(1):193–202PubMedCrossRef

Virmani R et al (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109(6):701–705PubMedCrossRef

Hwang CW, Wu D, Edelman ER (2001) Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104(5):600–605PubMedCrossRef

Pfisterer M et al (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48(12):2584–2591PubMedCrossRef

Camenzind E, Steg PG, Wijns W (2007) Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115(11):1440–1455; discussion 1455PubMedCrossRef

Lagerqvist B et al (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356(10):1009–1019PubMedCrossRef

10.

Brunner-La Rocca HP et al (2007) Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 370(9598):1552–1559CrossRef

11.

Schafer PE et al (2011) Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes 4(4):408–415PubMedCrossRef

12.

Silber S et al (2007) Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES): eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28.984 Patienten. Kardiologe 1:84–111CrossRef

13.

Silber S et al (2008) Medikamente freisetzende Koronarstents (DES) und Medikamente freisetzende Ballonkatheter (DEB). Aktualisierung des Positionspapiers der DGK. Clin Res Cardiol 97:548–563PubMedCrossRef

14.

Stone GW et al (2011) A prospective, randomized evaluation of a novel everolimus-eluting coronary stent the PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 57(16):1700–1708PubMedCrossRef

15.

Kereiakes DJ et al (2010) Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol 56(4):264–271PubMedCrossRef

16.

Kaiser C et al (2010) Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 363(24):2310–2319PubMedCrossRef

17.

Rasmussen K et al (2010) Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 375(9720):1090–1099PubMedCrossRef

18.

Kaiser C, Pfisterer M (2007) Increased rate of stent thrombosis with DES. Herz 32(4):296–300PubMedCrossRef

19.

Raber L et al (2011) Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 123(24):2819–2828PubMedCrossRef

20.

Stone GW et al (2010) Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362(18):1663–1674PubMedCrossRef

21.

Kedhi E et al (2010) Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375(9710):201–209PubMedCrossRef

22.

Fajadet J et al (2006) Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114(8):798–806PubMedCrossRef

23.

Kandzari DE et al (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48(12):2440–2447PubMedCrossRef

24.

Eisenstein EL et al (2009) Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2(12):1199–1207PubMedCrossRef

25.

Leon MB et al (2010) A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 55(6):543–554PubMedCrossRef

26.

Leon MB et al (2010) Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 3(10):1043–1050PubMedCrossRef

27.

Park DW et al (2010) Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 56(15):1187–1195PubMedCrossRef

28.

Serruys PW et al (2010) Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 363(2):136–146PubMedCrossRef

29.

Silber S et al (2011) Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 377(9773):1241–1247PubMedCrossRef

30.

Yeung AC et al (2011) Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries the RESOLUTE US clinical trial. J Am Coll Cardiol 57(17):1778–1783PubMedCrossRef

31.

Windecker S et al (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644):1163–1173PubMedCrossRef

32.

Garg S et al (2010) The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention 6(2):233–239PubMedCrossRef

33.

Chevalier B et al (2007) Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2(4):426–434PubMed

34.

Chevalier B et al (2009) Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial – Phase 2. Circ Cardiovasc Interv 2(3):188–195PubMedCrossRef

35.

Unverdorben M et al (2009) The paclitaxel-eluting Coroflex Please stent study (PECOPS I): the 3-year clinical follow-up. Catheter Cardiovasc Interv 74(5):674–682PubMedCrossRef

36.

Wiemer M et al (2010) The paclitaxel-eluting coroflex stent study II (PECOPS II) acute and 6-month clinical and angiographic follow-up, 1-year clinical follow-up. J Interv Cardiol 23(2):160–166PubMedCrossRef

37.

Byrne RA et al (2009) Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2(4):291–299PubMedCrossRef

38.

Erbel R et al (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369(9576):1869–1875PubMedCrossRef

39.

Serruys PW et al (2009) A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 373(9667):897–910PubMedCrossRef

40.

Beijk MA et al (2010) Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J 31(9):1055–1064PubMedCrossRef

41.

Wohrle J et al (2011) Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. Heart 97(16):1338–1342PubMedCrossRef

42.

Moschovitis A et al (2010) Randomised comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TiNOX trial. EuroIntervention 6(1):63–68PubMedCrossRef

43.

Scheller B et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355(20):2113–2124PubMedCrossRef

44.

Scheller B et al (2008) Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 97(10):773–781PubMedCrossRef

45.

Unverdorben M et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119(23):2986–2994PubMedCrossRef

46.

Rosli MA, Degenhardt R, Zambahari R et al (2011) Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 7:K83–K91CrossRef

47.

Cortese B et al (2010) Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 96(16):1291–1296PubMedCrossRef

48.

Beohar N et al (2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297(18):1992–2000PubMedCrossRef

49.

Win HK et al (2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297(18):2001–2009PubMedCrossRef

50.

Maisel WH (2007) Unanswered questions – drug-eluting stents and the risk of late thrombosis. N Engl J Med 356(10):981–984PubMedCrossRef

51.

Stettler C et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591):937–948PubMedCrossRef

52.

Zahn R et al (2010) Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. J Interv Cardiol 23(1):18–25PubMedCrossRef

53.

Palmerini T et al (2009) Ostial and midshaft lesions vs. bifurcation lesions in 1111 patients with unprotected left main coronary artery stenosis treated with drug-eluting stents: results of the survey from the Italian Society of Invasive Cardiology. Eur Heart J 30(17):2087–2094PubMedCrossRef

54.

Weisz G et al (2009) Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. J Am Coll Cardiol 53(17):1488–1497PubMedCrossRef

55.

Liistro F et al (2010) Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 yrs. J Am Coll Cardiol 55(7):613–616PubMedCrossRef

56.

Jain AK et al (2010) Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five registry. Heart 96(11):848–853PubMedCrossRef

57.

Lotan C et al (2009) Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2(12):1227–1235PubMedCrossRef

58.

Lasala JM et al (2009) Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program. Am J Cardiol 103(12):1663–1671PubMedCrossRef

59.

Stenestrand U et al (2010) Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 31(2):177–186PubMedCrossRef

60.

Garg P et al (2008) Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation 118(22):2277–2285PubMedCrossRef

61.

Latib A et al (2009) Clinical outcomes after unrestricted implantation of everolimus-eluting stents. JACC Cardiovasc Interv 2(12):1219–1226PubMedCrossRef

62.

Jensen LO et al (2010) Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol 105(11):1513–1519PubMedCrossRef

63.

Kereiakes DJ et al (2010) Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 56(25):2084–2089PubMedCrossRef

64.

Buch AN et al (2008) Outcomes after sirolimus- and paclitaxel-eluting stent implantation in patients with insulin-treated diabetes mellitus. Am J Cardiol 101(9):1253–1258PubMedCrossRef

65.

Frobert O et al (2009) Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 53(18):1660–1667PubMedCrossRef

66.

Kapur A et al (2010) Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 55(5):432–440PubMedCrossRef

67.

Banning AP et al (2010) Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 55(11):1067–1075PubMedCrossRef

68.

Mahmud E et al (2008) Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51(25):2385–2395PubMedCrossRef

69.

Kumbhani DJ et al (2008) The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. Am Heart J 155(4):640–647PubMedCrossRef

70.

Schächinger V, Herdeg C, Scheller B (2010) Best way to revascularize patients with main stem and three vessel lesions: patients should undergo PCI! Clin Res Cardiol 99(9):531–539PubMedCrossRef

71.

Pittl U, Kaiser C, Brunner-La Rocca HP et al (2006) Safety and efficacy of drug eluting stents versus bare metal stents in the primary angioplasty of patients with acute ST-elevation myocardial infarction: a prospective randomized study. Eur Heart J 27:650

72.

Kelbaek H et al (2008) Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation 118(11):1155–1162PubMedCrossRef

73.

Di Lorenzo EVA, Lanzillo T et al (2005) Paclitaxel and sirolimus implantation in patients with acute myocardial infarction (abstr). Circulation 112:U538

74.

Tierala I (2006) Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation – Should the Patients Get a Drug-Eluting or Normal Stent (HAAMUSTENT). http://www.cardiosource.com/clinicaltrials/trial.asp?trialID = 1492

75.

Hoeven BL van der et al (2008) Stent malapposition after sirolimus-eluting and bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: acute and 9-month intravascular ultrasound results of the MISSION! intervention study. JACC Cardiovasc Interv 1(2):192–201PubMedCrossRef

76.

Valgimigli M et al (2008) Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299(15):1788–1799PubMedCrossRef

77.

Laarman GJ et al (2006) Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355(11):1105–1113PubMedCrossRef

78.

Chechi T et al (2007) Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 20(4):282–291PubMedCrossRef

79.

Menichelli M et al (2007) Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49(19):1924–1930PubMedCrossRef

80.

Valgimigli M et al (2005) Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293(17):2109–2117PubMedCrossRef

81.

Spaulding C et al (2009) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355(11):1093–1104CrossRef

82.

Stone GW et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358(21):2218–2230PubMedCrossRef

83.

Diaz de la Llera LS et al (2007) Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 154(1):164 e1–164 e6

84.

Brar SS et al (2009) Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 53(18):1677–1689PubMedCrossRef

85.

Steg PG et al (2009) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 30(3):321–329PubMedCrossRef

86.

Daemen J et al (2007) Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 99(8):1027–1032PubMedCrossRef

87.

Campo G et al (2010) Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from the REAL registry. Int J Cardiol 140(2):154–160PubMedCrossRef

88.

Mauri L et al (2008) Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359(13):1330–1342PubMedCrossRef

89.

Baz JA et al (2008) Spanish cardiac catheterization and coronary intervention registry. 17th official report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990–2007). Rev Esp Cardiol 61(12):1298–1314PubMed

90.

Bonzel T et al (2008) Leitlinie Perkutane Koronare Intervention (PCI). Clin Res Cardiol 97(8):513–547PubMedCrossRef

91.

Colombo A, Latib A (2008) Treatment of drug-eluting stent restenosis with another drug-eluting stent: do not fail the second time! Rev Esp Cardiol 61(11):1120–1122PubMedCrossRef

92.

Alfonso F et al (2008) Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 52(20):1621–1627PubMedCrossRef

93.

Cosgrave J et al (2007) Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 153(3):354–359PubMedCrossRef

94.

Garg S et al (2007) Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheter Cardiovasc Interv 70(1):9–14PubMedCrossRef

95.

Mehilli J et al (2010) Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 55(24):2710–2716PubMedCrossRef

96.

Habara S, Mitsudo K, Kadota K, Goto T et al (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 4(2):149–154PubMedCrossRef

97.

Colombo A et al (2009) Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 119(1):71–78PubMedCrossRef

98.

Ferenc M et al (2008) Randomized trial on routine vs. Provisional T-stenting in the treatment of de novo coronary bifurcation lesions. Eur Heart J 29(23):2859–2867PubMedCrossRef

99.

Hildick-Smith D et al (2010) Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 121(10):1235–1243PubMedCrossRef

100.

Erglis A et al (2009) Randomized comparison of coronary bifurcation stenting with the crush versus the culotte technique using sirolimus eluting stents: the Nordic stent technique study. Circ Cardiovasc Interv 2(1):27–34PubMedCrossRef

101.

Steigen TK et al (2006) Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 114(18):1955–1961PubMedCrossRef

102.

Zamani P, Kinlay S (2011) Long-term risk of clinical events from stenting side-branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis. Catheter Cardiovasc Interv 77(2):202–212PubMedCrossRef

103.

Ferenc M et al (2010) Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. Am Heart J 159(3):454–461PubMedCrossRef

104.

Zhang F, Dong L, Ge J (2009) Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomised trials. Heart 95(20):1676–1681PubMedCrossRef

105.

Hakeem A et al (2009) Provisional vs. complex stenting strategy for coronary bifurcation lesions: meta-analysis of randomized trials. J Invasive Cardiol 21(11):589–595PubMed

106.

Thomas M et al (2006) Percutaneous coronary intervention for bifurcation disease. A consensus view from the first meeting of the European Bifurcation Club. EuroIntervention 2(2):149–153PubMed

107.

Niemela M et al (2011) Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 123(1):79–86PubMedCrossRef

108.

Schofer J et al (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362(9390):1093–1099PubMedCrossRef

109.

Ardissino D et al (2004) Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292(22):2727–2734PubMedCrossRef

110.

Mehilli J et al (2006) Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27(3):260–266PubMedCrossRef

111.

Pfisterer M et al (2009) Long-term benefit-risk balance of drug-eluting vs. Bare-metal stents in daily practice: Does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 30(1):16–24PubMedCrossRef

112.

Menozzi A et al (2009) Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J 30(17):2095–2101PubMedCrossRef

113.

Elezi S et al (2006) Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 48(7):1304–1309PubMedCrossRef

114.

Godino C et al (2008) Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). Am J Cardiol 102(8):1002–1008PubMedCrossRef

115.

Tanimoto S et al (2007) Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: lnsight into the RESEARCH and T-SEARCH registries. Catheter Cardiovasc Interv 69(1):94–103PubMedCrossRef

116.

Hermiller JB et al (2009) Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. Am Heart J 158(6):1005–1010PubMedCrossRef

117.

Bartorelli AL et al (2010) An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv 76(1):60–66PubMedCrossRef

118.

Unverdorben M et al (2010) Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 99(3):165–174PubMedCrossRef

119.

Colmenarez HJ et al (2010) Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol 55(17):1854–1866PubMedCrossRef

120.

Kelbaek H et al (2006) The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 47(2):449–455PubMedCrossRef

121.

Suttorp MJ et al (2006) Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114(9):921–928PubMedCrossRef

122.

Garcia-Garcia HM et al (2007) Three-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital-(RESEARCH) registry. Catheter Cardiovasc Interv 70(5):635–639PubMedCrossRef

123.

Kandzari DE et al (2009) Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. JACC Cardiovasc Interv 2(2):97–106PubMedCrossRef

124.

Rubartelli P et al (2010) Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. Eur Heart J 31(16):2014–2020PubMedCrossRef

125.

Patel MR et al (2009) ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 119(9):1330–1352PubMedCrossRef

126.

Wijns W et al (2010) Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 31(20):2501–2555PubMedCrossRef

127.

Tamburino C et al (2009) Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes. Am J Cardiol 103(2):187–193PubMedCrossRef

128.

Kim YH et al (2009) Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 120(5):400–407PubMedCrossRef

129.

Biondi-Zoccai GG et al (2008) A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. Am Heart J 155(2):274–283PubMedCrossRef

130.

Pandya SB et al (2010) Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis. JACC Cardiovasc Interv 3(6):602–611PubMedCrossRef

131.

Erglis A et al (2007) A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 50(6):491–497PubMedCrossRef

132.

Palmerini T et al (2008) Two-year clinical outcome with drug-eluting stents versus bare-metal stents in a real-world registry of unprotected left main coronary artery stenosis from the Italian Society of Invasive Cardiology. Am J Cardiol 102(11):1463–1468PubMedCrossRef

133.

Buszman PE et al (2009) Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol 54(16):1500–1511PubMedCrossRef

134.

Seung KB et al (2008) Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 358(17):1781–1792PubMedCrossRef

135.

Wu X et al (2010) Comparison of long-term (4-year) outcomes of patients with unprotected left main coronary artery narrowing treated with drug-eluting stents versus coronary-artery bypass grafting. Am J Cardiol 105(12):1728–1734PubMedCrossRef

136.

White AJ et al (2008) Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. JACC Cardiovasc Interv 1(3):236–245PubMedCrossRef

137.

Rodes-Cabau J et al (2008) Nonrandomized comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians. Circulation 118(23):2374–2381PubMedCrossRef

138.

Brener SJ et al (2008) Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. Am J Cardiol 101(2):169–172PubMedCrossRef

139.

Park DW et al (2010) Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) registry. J Am Coll Cardiol 56(17):1366–1375PubMedCrossRef

140.

Chieffo A et al (2010) 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience. JACC Cardiovasc Interv 3(6):595–601PubMedCrossRef

141.

Toyofuku M et al (2009) Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Circulation 120(19):1866–1874PubMedCrossRef

142.

Meliga E et al (2009) Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). Int J Cardiol 137(1):16–21PubMedCrossRef

143.

Montalescot G et al (2009) Unprotected left main revascularization in patients with acute coronary syndromes. Eur Heart J 30(19):2308–2317PubMedCrossRef

144.

Naik H et al (2009) A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc Interv 2(8):739–747PubMedCrossRef

145.

Lee MS et al (2010) Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. Am J Cardiol 105(11):1540–1544PubMedCrossRef

146.

Takagi H, Matsui M, Umemoto T (2010) Increased late mortality with percutaneous stenting for unprotected left main coronary artery stenosis relative to coronary artery bypass grafting: a meta-analysis of observational studies. J Thorac Cardiovasc Surg 139(5):1351–1353PubMedCrossRef

147.

Buszman PE et al (2008) Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. J Am Coll Cardiol 51(5):538–545PubMedCrossRef

148.

Serruys PW et al (2009) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360(10):961–972PubMedCrossRef

149.

Morice MC et al (2010) Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 121(24):2645–2653PubMedCrossRef

150.

Park SJ et al (2011) Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 364(18):1718–1727PubMedCrossRef

151.

Garg S, Serruys PW (2010) Coronary stents: current status. J Am Coll Cardiol 56(10 Suppl):S1–S42PubMedCrossRef

152.

Meliga E et al (2008) Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) registry. J Am Coll Cardiol 51(23):2212–2219PubMedCrossRef

153.

Lee JY et al (2009) Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. J Am Coll Cardiol 54(9):853–859PubMedCrossRef

154.

Mehilli J et al (2009) Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 53(19):1760–1768PubMedCrossRef

155.

Vaquerizo B et al (2009) Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry. Circulation 119(17):2349–2356PubMedCrossRef

156.

Hamilos M et al (2009) Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 120(15):1505–1512PubMedCrossRef

157.

Park SJ et al (2009) Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis. Circ Cardiovasc Interv 2(3):167–177PubMedCrossRef

158.

Sheiban I et al (2009) Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study). J Am Coll Cardiol 54(13):1131–1136PubMedCrossRef

159.

Lee JY et al (2011) Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. J Am Coll Cardiol 57(12):1349–1358PubMedCrossRef

160.

Brilakis ES et al (2010) Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: a Multicenter Safety Surveillance) program. JACC Cardiovasc Interv 3(7):742–750PubMedCrossRef

161.

Vermeersch P et al (2007) Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 50(3):261–267PubMedCrossRef

162.

Brilakis ES et al (2009) A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 53(11):919–928PubMedCrossRef

163.

Jeger RV et al (2009) Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 112(1):49–55PubMedCrossRef

164.

Brilakis ES, Saeed B, Banerjee S (2010) Drug-eluting stents in saphenous vein graft interventions: a systematic review. EuroIntervention 5(6):722–730PubMedCrossRef

165.

Lee MS et al (2010) Comparison by meta-analysis of drug-eluting stents and bare metal stents for saphenous vein graft intervention. Am J Cardiol 105(8):1076–1082PubMedCrossRef

166.

Sanchez-Recalde A et al (2010) Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis. EuroIntervention 6(1):149–160PubMedCrossRef

167.

Meier P et al (2010) Drug-eluting versus bare-metal stent for treatment of saphenous vein grafts: a meta-analysis. PLoS One 5(6):e11040PubMedCrossRef

168.

Mehta SR et al (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748):1233–1243PubMedCrossRef

169.

Mehta SR, Eikelboom JW, Yusuf S (2011) Double-dose clopidogrel in patients undergoing PCI for ACS – authors‘ reply. Lancet 377(9762):298CrossRef

170.

Kleber FX et al, on behalf of the German Drug-Eluting Balloon Consensus Group (2011) How to use the drug-eluting nalloon. Recommendations by the German consensus group. EuroIntervention 7(K):125–128CrossRef

171.

Neubauer H et al (2009) Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 98(9):533–540PubMedCrossRef

172.

Price MJ et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097–1105PubMedCrossRef

173.

Abraham NS et al (2010) ACCF/ACG/AHA 2010 Expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122(24):2619–2633PubMedCrossRef

174.

Payne CD et al (2007) Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 50(5):555–562PubMedCrossRef

175.

Brandt JT et al (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66 e9–66 e16PubMedCrossRef

176.

Wiviott SD et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001–2015PubMedCrossRef

177.

Wiviott SD et al (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371(9621):1353–1363PubMedCrossRef

178.

Storey RF et al (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50(19):1852–1856PubMedCrossRef

179.

Husted S et al (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27(9):1038–1047PubMedCrossRef

180.

Wallentin L et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRef

181.

Cannon CP et al (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711):283–293PubMedCrossRef

182.

Nabauer M et al (2009) The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace 11(4):423–434PubMedCrossRef

183.

Connolly S et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367(9526):1903–1912PubMedCrossRef

184.

Lip GY, Huber K, Andreotti F et al (2010) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 103:13–28PubMedCrossRef

185.

Vicenzi MN et al (2006) Coronary artery stenting and non-cardiac surgery – a prospective outcome study. Br J Anaesth 96(6):686–693PubMedCrossRef

186.

Hoffmeister HM, Bode C, Darius H et al (2010) Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Kardiologe 4:365–374CrossRef

187.

Mauri L et al (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356(10):1020–1029PubMedCrossRef

188.

Iakovou I et al (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17):2126–2130PubMedCrossRef

189.

Ong AT et al (2005) Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45(12):2088–2092PubMedCrossRef

190.

Cutlip DE et al (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17):2344–2351PubMedCrossRef

191.

Holmes DR Jr et al (2007) Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 50(2):109–118PubMedCrossRef

192.

Aoki J et al (2007) Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv 69(3):380–386PubMedCrossRef

193.

Lee MS et al (2007) Stent fracture associated with drug-eluting stents: clinical characteristics and implications. Catheter Cardiovasc Interv 69(3):387–394PubMedCrossRef

194.

Nakazawa G et al (2009) Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 54(21):1924–1931PubMedCrossRef

195.

Aoki A et al (2007) Late multiple stent fractures following deployment of sirolimus-eluting stents for diffuse right coronary artery stenosis. Int Heart J 48(6):767–772PubMedCrossRef

196.

Shaikh F et al (2008) Stent fracture, an incidental finding or a significant marker of clinical in-stent restenosis? Catheter Cardiovasc Interv 71(5):614–618PubMedCrossRef

197.

McFadden EP et al (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444):1519–1521PubMedCrossRef

198.

Cook S et al (2007) Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115(18):2426–2434PubMedCrossRef

199.

Hoeven BL van der et al (2008) Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 51(6):618–626PubMedCrossRef

200.

Morice MC et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346(23):1773–1780PubMedCrossRef

201.

Byrne RA et al (2009) Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial. Eur Heart J 30(20):2441–2449PubMedCrossRef

202.

Kereiakes DJ et al (2010) Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention The SPIRIT III (a clinical evaluation of the investigational device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the treatment of subjects with de novo native coronary artery lesions) and SPIRIT IV (elinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions) randomized trials. JACC Cardiovasc Interv 3(12):1229–1239PubMedCrossRef

203.

Ormiston JA et al (2010) Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv 3(6):556–564PubMedCrossRef

204.

Cremers B et al (2010) Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol 58(5):583–588PubMed

205.

Stone GW et al (2005) Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294(10):1215–1223PubMedCrossRef

206.

Kastrati A et al (2005) Paclitaxel-eluting stent versus Sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease. J Am Coll Cardiol 45(9):22-3–22-3

Titel: Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter
Positionspapier der DGK 2011
verfasst von: Prof. Dr. B. Scheller
B. Levenson
M. Joner
R. Zahn
V. Klauss
C. Naber
V. Schächinger
A. Elsässer
Arbeitsgruppe Interventionelle Kardiologie (AGIK) der Deutschen Gesellschaft für Kardiologie (DGK)
Publikationsdatum: 01.12.2011
Verlag: Springer-Verlag
Erschienen in: Die Kardiologie / Ausgabe 6/2011
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-011-0375-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Digitale Mammographien links in kraniokaudaler Projektion./© Weigel, S. et al. / all rights reserved Springer Medizin Verlag GmbH, Operation bei Blasenkrebs/© anistidesign / Fotolia, Medizinische Fachangestellte sitzt erschöpft auf der Treppe/© Courtney Haas / peopleimages.com /stock.adobe.com (Symbolbild mit Fotomodell), Mann wird von Ärztin untersucht/© Tashi-Delek, Getty Images, iStock (Symbolbild mit Fotomodellen)

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Rhythmusstörungen bei Schwangeren

„Standard operating procedures“ zur Umsetzung der Leitlinien bei Patienten mit Brustschmerz

Innovative Therapien

Massive Verdickung des interatrialen Septums als Zufallsbefund